Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis

  title={Randomized controlled trial of cannabis‐based medicine in spasticity caused by multiple sclerosis},
  author={Christine Collin and Paul T. G. Davies and I K Mutiboko and S. Ratcliffe},
  journal={European Journal of Neurology},
Symptoms relating to spasticity are common in multiple sclerosis (MS) and can be difficult to treat. We have investigated the efficacy, safety and tolerability of a standardized oromucosal whole plant cannabis‐based medicine (CBM) containing Δ‐9 tetrahydrocannabinol (THC) and cannabidiol (CBD), upon spasticity in MS. A total of 189 subjects with definite MS and spasticity were randomized to receive daily doses of active preparation (n = 124) or placebo (n = 65) in a double blind study over 6… 

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review

Evidence is found that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms and subjective assessment of symptom relief did often show significant improvement post-treatment.

MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial

The study met its primary objective to demonstrate the superiority of CE over placebo in the treatment of muscle stiffness in MS and was supported by results for secondary efficacy variables.

Cannabinoid Effect and Safety in Spasticity Following Stroke: A Double-Blind Randomized Placebo-Controlled Study

Nabiximols use is probably safe in stroke patients, therefore cannabinoid usefulness may be further investigated, as primary and secondary efficacy outcome measures did not change from baseline during nabximols treatment relative to placebo.

Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis

The findings confirm the clinical benefit of Sativex on MS spasticity and the lack of corresponding changes in corticospinal excitability and on the monosynaptic component, of the stretch reflex, although in a limited sample size, points to the involvement of other spinal and supraspinal mechanisms in the physiopathology ofSpasticity in progressive MS.

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies

Delta-9-tetrahydrocannabinol: cannabidiol was well tolerated in the evaluated studies in the same way as in the RCTs and no new or unexpected adverse events or safety signals were reported in everyday clinical practice.

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

No new safety concerns were identified with chronic Sativex treatment, and serious AEs were uncommon, and patients who remained in the study reported continued benefit.

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis

Clinical studies on cannabis-based medicine extract (CBME), in particular nabiximols, in spasticity, as well as pain, and bladder dysfunction in MS are analyzed.

Assessing the Neurophysiological Effects of Cannabinoids on Spasticity in Multiple Sclerosis

Cannabinoids do not exert beneficial effects on MS-related spasticity through a direct action on the motor system as assessed by fMRI and electrophysiological methods.

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

The current understanding of cannabinoid biology and the value of cannabinoids as a symptomatic treatment option addressing spasticity in patients with MS are reviewed.



Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

These data provide limited evidence for a longer term treatment effect of cannabinoids in multiple sclerosis, and a long term placebo controlled study is now needed to establish whether cannabinoids may have a role beyond symptom amelioration in MS.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

CBM was generally well tolerated, although more patients on CBM than placebo reported dizziness, dry mouth, and somnolence, and Cognitive side effects were limited to long-term memory storage.

The therapeutic value of cannabinoids in MS: real or imaginary?

This issue of Multiple Sclerosis contains three interesting papers that claim beneficial effects of cannabinoids on symptoms in MS patients. The randomized, double-blind, placebo-controlled,

Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

Urinary urgency, the number and volume of incontinence episodes, frequency and nocturia all decreased significantly following treatment with cannabis-based medicinal extracts, suggesting that cannabis- based medicinal extracts are a safe and effective treatment for urinary and other problems in patients with advanced MS.

Anti-spasticity agents for multiple sclerosis.

The rationale for treating features of the upper motor neurone syndrome must be better understood and sensitive, validated spasticity measures need to be developed.

Prevalence and treatment of spasticity reported by multiple sclerosis patients

In the focused survey, ITBG reported lower levels of spasticity than ORALG, less stiffness in the legs, less pain and fewer spasms at any time, which can significantly impact QOL parameters by reducing spasms, pain and fatigue.

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

A standardized Cannabis sativa plant extract might lower spasm frequency and increase mobility with tolerable side effects in MS patients with persistent spasticity not responding to other drugs.

Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.

There was significant improvement in patient ratings of spasticity compared to placebo at doses greater than 7.5 mg, suggesting a role for THC in the treatment ofSpasticity in multiple sclerosis.